Sort Key 9
Title Alternative Drug-induced liver injury due to the long-term oral administration of rosuvastatin
FullText URL 127_219.pdf
Author Oonishi, Ayano| Kariyama, Kazuya| Wakuta, Akiko| Nishimura, Mamoru| Nouso, Kazuhiro|
Abstract A 67-year-old man was admitted to our hospital presenting with a liver injury. He had used several types of oral medication for the prior 2 years, including rosuvastatin calcium for hypertension, hyperlipidemia, and prostatic hypertrophy. His liver dysfunction was noted for the first time in February 2013, and at re-examination in March 2013 he showed exacerbation of the liver dysfunction, he was admitted to our hospital at that time. We stopped all of his oral medications, and his liver function improved steadily. We conducted a drug-induced lymphocyte transformation test (DLST), and the rosuvastatin calcium result was positive. He was diagnosed as having a drug-induced (by rosvastatin calcium) liver injury. He resumed oral medications other than rosuvastatin calcium from the time of discharge, with no exacerbation of liver dysfunction since then. Reports of drug-induced liver injury due to drugs with a long-term oral administration are extremely rare. We discuss the relevant literature herein.
Keywords 薬物性肝障害(drug induced liver injury) ロスバスタチンカルシウム(Rosuvastatin) スタチン(statin) DLST
Note 症例報告(Case Reports)
Publication Title 岡山医学会雑誌
Published Date 2015-12-01
Volume volume127
Issue issue3
Publisher 岡山医学会
Publisher Alternative Okayama Medical Association
Start Page 219
End Page 222
ISSN 0030-1558
NCID AN00032489
Content Type Journal Article
Related Url isVersionOf
language 日本語
Copyright Holders Copyright (c) 2015 岡山医学会
File Version publisher
Refereed True
DOI 10.4044/joma.127.219
NAID 130005116815
Eprints Journal Name joma
References 1)三藤留美, 岩佐元雄, 足立幸彦 : 薬物性肝障害の実態と疫学 : 医学のあゆみ (2005) 214, 765-769. 2)Takikawa H, Murata Y, Horiike N, Fukui H, Onji M : Drug-induced liver injury in Japan - an analysis of 1676 cases between 1997 and 2006. Hepatol Res (2009) 39, 427-431. 3)滝川 一, 恩地森一, 高瀬頼雪, 村田洋介, 谷口英明, 伊藤 正, 渡辺真彰, 綾田 穣, 前田直人, 野本 稔, 村田浩之, 大森 茂, 他 : DDW-J 2004ワークショップ薬物性肝障害診断基準案の提案. 肝臓 (2005) 46, 85-90. 4)Endo A, Kuroda M, Tanzawa K : Competitive inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase by ML-236A and ML 236B fugal metabolites, having hypocholesterolesterolemic activity. FEBS Letters (1976) 72, 323-326. 5)三上 繁, 若松 徹, 大西和彦, 清水史郎, 秋本政秀 : スタチン製剤. 薬物性肝障害の新展開―疑問点の集約とその解決を探る. 肝胆膵 (2014) 68, 231-234. 6)Maeda A, Yano T, Itoh Y, Kakumori M, Kubota T, Egashira N, Oishi R : Down-regulation of RhoA is involved in the cytotoxic action of lipophilic statins in HepG2 cells. Atherosclerosis (2010) 208, 112-118. 7)Rosenson RS : Current overview of statin-induced myopathy. Am J Med (2004) 116, 408-416. 8)大石了三 : 脂質異常症治療薬. 臨牀と研究 (2011) 88, 1235-1241. 9)Mckenney JM : Final Conclusions and Recommendations of the National Lipid Association Statin Safety Assessment Task Force. Am J Cardiol (2006) 97, C89-94. 10)Krahenbuhl S, Brauchi Y, Kummer O, Bodmer M, Trendelenburg M, Drewe J, Haschke M : Acute liver failure in two patients with regular alchol consumption ingesting paracetamol at therapeutic dosage. Digestion (2007) 75, 232-237. 11)Thummel KE, Slattery JT, Ro H, Chien JY, Nelson SD, Lown KE, Watkins PB : Ethanol and production of the hepatotoxic metabolite of acetaminophen in healthy adults. Clin Pharmacol Ther (2000) 67, 591-599. 12)Suzuki A, Yuen N, Walsh J, Papay J, Hunt CM, Diehl AM : Co-medications that modulate liver injury and repair influence clinical outcome of acetaminophen-associated liver injury. Clin Gastroenterol Hepatol (2009) 7, 882-888. 13)入江 真, 横山圭二, 櫻井邦俊, 岩下英之, 上田秀一, 森原大輔, 西澤新也, 阿南 章, 竹山康章, 坂本雅晴, 岩田 郁, 釈迦堂敏, 他 : 長期アムロジピン, ロキソプロフェンナトリウム服用にて高度の黄疸を伴った薬剤性肝障害の1例. 肝臓 (2010) 51, 169-174. 14)藤瀬 幸, 孝田雅彦, 桑本聡史, 三好謙一, 木科 学, 加藤 順, 徳永志保, 岡野淳一, 北浦 剛, 武田洋正, 村脇義和 : 長期間アンジオテンシンⅡ受容体拮抗薬ロサルタン服用後に発症した薬物性肝障害の1例. 肝臓 (2013) 54, 600-606. 15)神保りか, 吉岡篤史, 高橋有香, 小野圭一, 足立洋祐, 小島 茂, 武田雄一, 野内俊彦, 清水誠一郎 : トラニラストが原因と考えられた薬物性肝障害の5症例. 日消誌 (2005) 102, 1051-1054. 16)清水直容 : 医薬品によるアレルギー反応の客観的指標―とくにDLSTの実情とその有用性― : 有害事象の診断学―医薬品と有害事象との因果関係判定の手引―, 清水直容編, 臨床評価刊行会, 東京 (2003) pp49-74. 17)安部和道, 今泉博道, 林  学, 岡井 研, 菅野有紀子, 高橋敦史, 大平弘正 : 検査値の読み方―DLSTは意味があるのか?肝胆膵 (2014) 68, 155-160. 18)Punthakee Z, Scully LJ, Guindi MM, Ooi TC : Liver fibrosis attributed to lipid lowering medications : two cases. J Intern Med (2001) 250, 249-254.
Author Wakuta, Akiko|
Published Date 2012-03-23
Publication Title
Content Type Thesis or Dissertation